

Jun 27, 2024

## Mutant generation in Streptococcus mitis strain B6

DOI

[dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1](https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1)

Samantha King<sup>1</sup>

<sup>1</sup>Nationwide Children's Hospital

King lab



Samantha King

Nationwide Children's Hospital

OPEN  ACCESS



DOI: [dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1](https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1)

**Protocol Citation:** Samantha King 2024. Mutant generation in Streptococcus mitis strain B6. **protocols.io**  
<https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1>

**License:** This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working

**We use this protocol and it's working**

**Created:** June 26, 2024

**Last Modified:** June 27, 2024

**Protocol Integer ID:** 102478

**Keywords:** Transformation, mutagenesis, Streptococcus mitis B6

**Funders Acknowledgement:**  
**American Heart Association**  
**Grant ID:** 19TPA34760750

## Abstract

This protocol is the methodology that we have successfully employed to generate and confirm insertion deletion mutants in *Streptococcus mitis* strain B6. Attached to the protocol is a file that includes primers for the MonX mutation

## Attachments



**B6 mutagenesis of Mo...**

14KB

## Materials

**Table 1: Primers Used in This Study**

A	B	C	D
Target	Name	Sequence 5' to 3'	Location (accession no.)
Spec	S1	CGATTTTCGTTCTGAATAC	5418–5399 (KM009065)
	S2	TATGCAAGGGTTTATTGTTTTTC	4265–4286 (KM009065)
pJet	P1	CGACTCACTATAGGGAGAGCGGC	310-332 (EF694056.1)
	P2	AAGAACATCGATTTTCCATGGCAG	405-428 (EF694056.1)

## Safety warnings

⚠ Appropriate biosafety procedures need to be followed

## *Streptococcus mitis* B6 mutagenesis protocol

1

### **Creation of a plasmid construct**

- 1.1 The regions upstream and downstream of the region to be deleted were amplified using primers 1 and 2, and 3 and 4, respectively. These primers were designed to contain appropriate overhangs to allow In-fusion with pJET 1.2/blunt and the antibiotic resistance cassette.
- 1.2 The spectinomycin resistance cassette (*aad9*) was amplified using primers S1 and S2
- 1.3 PCR products were then purified with a Qiagen PCR Purification Kit
- 1.4 The three fragments for each mutant construct were cloned into pJET 1.2/Blunt (Thermo Fisher Scientific) using In-Fusion Snap Assembly (Takara) and transformed into *Escherichia coli* stellar competent cells.
- 1.5 Transformants were selected on LB agar plates supplemented with ampicillin (100 µg/ml) and incubated at 37°C overnight
- 1.6 The resulting colonies were confirmed as ampicillin resistant by streaking on a new LB agar plate supplemented with ampicillin (100 µg/ml).
- 1.7 Transformants were screened by colony PCR using pJET 1.2/blunt Fwd and Rev primers.
- 1.8 For transformants giving an appropriate PCR product, a 5 mL LB culture supplemented with ampicillin (100 µg/ml) was grown overnight at 37 °C with shaking at 200 rpm.
- 1.9 The plasmid was then purified using Qiagen Miniprep Kit and confirmed by sequencing

### **2 Transformation of *S. mitis* B6**

- 2.1 Strains were growth at 37°C in C+Y pH8 [1] – starting at a low inoculum i.e. from a plate or diluting from a culture 1:100 (starting optical density at 600nm [OD<sub>600</sub>] = 0.03 to 0.05).

- 2.2 When the culture was close to  $OD_{600} = 0.1$ , 950  $\mu$ l of C+Y pH 8.0 medium was added to a 1.5 ml tube with 10  $\mu$ l of 100 mM  $CaCl_2$ , 2  $\mu$ l of competence stimulating peptide (CSP) (EMRKPDGALFNLFRRR - 1 mg/ml), and 150 ng of DNA. A no DNA control tube is included to account for potential contamination. These tubes were prewarmed in a waterbath to 37°C.
- 2.3 When the culture reached an  $OD_{600}$  of 0.10 to 0.12, 50  $\mu$ l of culture was added to the prewarmed tubes.
- 2.4 Tubes were incubated in a waterbath at 37 °C for 2 hr.
- 2.5 Reactions were pelleted by centrifugation and resuspended in approximately 100  $\mu$ l of media. This was plated on selective Tryptic Soy Agar (TSA) plates spread with 5000 U catalase (Worthington Biochemical Corporation).
- 2.6 Plates were incubated at 37°C in 5% CO<sub>2</sub> overnight and then patched onto selective plates.
- 3 **Confirmation of putative transformants**
  - 3.1 Putative transformants were grown in tryptic soy broth and DNA prepared as previously described [2].
  - 3.2 The mutations were confirmed by PCR and sequencing (using primers S1 and S2) or genome sequencing.

## Protocol references

1. LACKS S, HOTCHKISS RD. A study of the genetic material determining an enzyme in *Pneumococcus*. *Biochim Biophys Acta*. 1960;39:508-18. doi: 10.1016/0006-3002(60)90205-5. PubMed PMID: 14413322.
2. Gaytán MO, Singh AK, Woodiga SA, Patel SA, An SS, Vera-Ponce de León A, et al. A novel sialic acid-binding adhesin present in multiple species contributes to the pathogenesis of Infective endocarditis. *PLoS Pathog*. 2021;17(1):e1009222. Epub 20210119. doi: 10.1371/journal.ppat.1009222. PubMed PMID: 33465168; PubMed Central PMCID: PMC7846122.